Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5218711
Max Phase: Preclinical
Molecular Formula: C17H17ClFN5O3S2
Molecular Weight: 457.94
Associated Items:
ID: ALA5218711
Max Phase: Preclinical
Molecular Formula: C17H17ClFN5O3S2
Molecular Weight: 457.94
Associated Items:
Canonical SMILES: Cn1ncc(S(=O)(=O)N2CC[C@H](C(=O)Nc3ccc4scnc4c3)[C@@H](F)C2)c1Cl
Standard InChI: InChI=1S/C17H17ClFN5O3S2/c1-23-16(18)15(7-21-23)29(26,27)24-5-4-11(12(19)8-24)17(25)22-10-2-3-14-13(6-10)20-9-28-14/h2-3,6-7,9,11-12H,4-5,8H2,1H3,(H,22,25)/t11-,12-/m0/s1
Standard InChI Key: IYISGZCTJCPVJL-RYUDHWBXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 457.94 | Molecular Weight (Monoisotopic): 457.0445 | AlogP: 2.67 | #Rotatable Bonds: 4 |
Polar Surface Area: 97.19 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.40 | CX Basic pKa: 2.28 | CX LogP: 1.39 | CX LogD: 1.39 |
Aromatic Rings: 3 | Heavy Atoms: 29 | QED Weighted: 0.65 | Np Likeness Score: -2.22 |
1. Capstick RA, Whomble D, Orsi DL, Felts AS, Rodriguez AL, Vinson PN, Chang S, Blobaum AL, Niswender CM, Conn PJ, Jones CK, Lindsley CW, Han C.. (2022) Discovery of a potent M5 antagonist with improved clearance profile. Part 1: Piperidine amide-based antagonists., 76 [PMID:36113671] [10.1016/j.bmcl.2022.128988] |
Source(1):